item management s discussion and analysis of financial condition and results of operations year ended january   nine months ended january  and the fiscal year ended april  during the year ended january   the company reported a net loss of  during this period the company had no contract or product revenues 
investment earnings on cash for twelve months was approximately the same as the  earned in the nine months ended january  due to lower average cash balances 
research and development expenditures were  which represented an increase in average quarterly research and development expenditures from about million per quarter in the nine months ended january  to about million per quarter for the year ended january  this increase was budgeted for and related to the on going and planned additional human clinical trials 
during the nine months ended january   the company reported a net loss of  including non cash interest expense of  relating to the convertible debenture described below 
during this period the company had no contract or product revenues 
investment earnings on cash increased  to  due to higher average cash balances 
research and development expenditures were  which represented an increase in average quarterly research and development expenditures from about million per quarter in the year ended april  to about million per quarter for the nine months ended january  this increase was budgeted for and related to the on going and planned additional human clinical trials 
during the fiscal year ended april   the company reported a net loss of  during this period the company had no contract or product revenues 
investment earnings on cash decreased to  due to lower average cash balances 
research and development expenditures increased to  this increase was budgeted for and related to the on going and planned additional human clinical trials 
in fiscal  the company implemented statement of financial accounting standards sfas no 
 reporting comprehensive income and sfas no 
 employers disclosure about pensions and other postretirement benefits 
these new accounting standards had no impact on the company s financial statements since the company does not have elements of comprehensive income other than net loss  nor does it provide pension or other postretirement benefits 
in june  the fasb issued sfas no 
 accounting for derivative instruments and hedging activities which will not have an effect on the company s financial statements since the company does not engage in the transaction of derivative instruments and hedging activities 
many computer programs were written to use only two digits to identify the year 
thus  a computer program could read the digits as the year or as the year in addition  microprocessors embedded in many operating facilities such as communication systems may cause equipment malfunctions because of the year date change 
failure by third parties upon which the company relies or by the company to address the year issue could cause material loss to the company 
management has completed the awareness and assessment phase of a comprehensive program to address the year issue 
the company utilizes standard off the shelf software and will implement any necessary vendor upgrades and modifications to assure continued functionality 
at present  management does not expect that material incremental costs will be incurred in the aggregate or in any single future year 
the company has also begun to assess the year compliance efforts of external parties upon which the company relies 
the company is developing contingency plans for addressing any material failure to deal with the year date change that will address the company s exposure to year noncompliance by third parties 
even though the company s planned software and hardware modifications and system upgrades should adequately address year issues  there can be no assurance that unforeseen difficulties will not arise 
there is no assurance that the failure of any external party to resolve its year issues would not have a material adverse effect on the company 
inflation and changing prices have not had a significant effect on continuing operations and are not expected to have any material effect in the foreseeable future 
dividend  interest and other income were primarily derived from money market accounts 
liquidity and capital resources the company had financed its operations since inception through the sale of its equity securities and  to a lesser extent  operating revenues from r d limited partnerships to conduct research and development 
these funds provided the company with the resources to acquire staff  construct its research and development facility  acquire capital equipment and to finance technology and product development  manufacturing and clinical trials 
in june  aphton and smithkline beecham signed a collaboration and license agreement for a worldwide strategic alliance for aphton s anti gnrh immunogen 
the agreement covers the diagnosis  treatment and prevention of gnrh related cancers and other diseases in humans 
human cancer indications for aphton s gnrh pharmaccine are prostate  breast  ovarian and endometrial cancer 
additional medical indications for gnrh pharmaccine are endometriosis  polycystic ovaries  uterine fibroids  infertility and precocious puberty 
under terms of the agreement  smithkline beecham received exclusive rights worldwide to aphton s gnrh related patents and proprietary technology 
aphton and smithkline beecham are collaborating in a joint product development program 
smithkline beecham is responsible for funding all costs of product development  clinical trials and regulatory approvals  and for worldwide marketing and distribution of approved products 
the agreement uses a royalty mechanism based on product sales  in dollars  worldwide to determine aphton s revenues 
as part of the agreement  smithkline beecham made an equity investment of  for shares of newly issued aphton common stock 
in addition  smithkline beecham has granted aphton an irrevocable two year option which can be exercised by aphton at any time during that period to sell to smithkline beecham additional shares of newly issued aphton common stock for a value of  at the then current market price 
if and when aphton exercises that option  smithkline beecham shall have the right for days to purchase a number of additional shares of newly issued aphton common stock for a value of  at the then current market price 
on june   the company announced that it had received proceeds of  from the closing of a private financing of common stock 
the company issued  shares of common stock with a year warrant for  shares exercisable at per share 
in april  the company issued a  senior redeemable convertible debenture 
during the nine months ended january  the debenture and related interest was converted into  shares of the company s common stock 
non cash interest on such debt amounted to approximately  in the nine months ended january  and  in fiscal on february  aphton signed an agreement with pasteur merieux connaught pmc rhone poulenc group  a leader in medical science and research and the world s largest vaccine manufacturer and marketer  for a strategic alliance for all human cancer applications of the company s anti gastrin immunogen including stomach  colorectal  liver and pancreatic cancers 
under the terms of the twenty year license and co promotion agreement  aphton will be responsible for product development  clinical trials and regulatory agency approvals  and pmc will be responsible for promotion  advertising  marketing  distribution and sales of its anti gastrin immunogen in the united states  canada  europe including the cis countries and mexico 
in addition  aphton and pmc will enter into agreements providing for a the supply of anti gastrin immunogen from aphton to pmc  and b the supply of certain components of anti gastrin immunogen as well as other aphton products from pmc to aphton 
pmc will fund the costs associated with product introduction  promotion  advertising and marketing throughout the territory covered by the agreement 
under the terms of the agreement  in addition to upfront consideration aggregating million including million cash and the supply commitment of material suitable for human use of million  aphton will receive the majority of the profits from sales of its anti gastrin immunogen with the balance of profits to be retained by pmc 
the supply commitment of materials suitable for human use consists of diphtheria toxoid and or tetanus toxoid 
aphton may use some or all of the unconditional supply commitment in the product under development with pmc or aphton may use some or all of the supply commitment on other current product lines or on research and development 
the company anticipates that its existing capital resources which are composed primarily of cash and short term cash investments  including the proceeds of its private placements and interest thereon  and available capital sources  would enable it to maintain its currently planned operations into the year the company s working capital and capital requirements will depend upon numerous factors  including the following the progress of the company s research and development program  preclinical testing and clinical trials  the timing and cost of obtaining regulatory approvals  the levels of resources that the company devotes to product development  manufacturing and marketing capabilities  technological advances  competition  and collaborative arrangements or strategic alliances with other drug companies  including the further development  manufacturing and marketing of certain of the company s products and the ability of the company to obtain funds from such strategic alliances or from other sources 

